title: Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. A prospective, controlled pilot study.
abstract: BACKGROUND
  Recently, promising disease modifying effects of low dose corticosteroid treatment in primary biliary cirrhosis have been reported. However, steroid-induced bone loss constitutes a potential drawback of this treatment option.
  
  
  OBJECTIVE
  To assess whether etidronate can reduce bone loss during corticosteroid treatment.
  
  
  METHODS
  Twelve primary biliary cirrhosis patients (all Child-Pugh Class A), treated with prednisone in the context of a 1-year placebo-controlled pilot study with prednisone (maintenance dose 10 mg daily), and azathioprine (50 mg daily), were randomized to receive either cyclical etidronate (400 mg daily, during 2 weeks) alternated with calcium 500 mg daily during 11 weeks or calcium alone. All patients had been receiving ursodeoxycholic acid during at least 1 year and this treatment was continued. Bone mass was measured in the lumbar spine and the femoral neck by dual energy X-ray absorptiometry before and after 3 and 12 months of treatment. Markers of bone formation (serum osteocalcin, procollagen-I-propeptide) and bone resorption (urinary deoxypyridinoline and calcium) were also monitored.
  
  
  RESULTS
  The mean lumbar bone mineral density did not significantly change in the patients taking etidronate + calcium, in contrast to patients treated with calcium alone (+0.4 vs. -3.0%; p = 0.01). Changes in femoral bone mineral density and markers of bone turnover did not significantly differ between both groups. No adverse effects of etidronate were noted.
  
  
  CONCLUSIONS
  Cyclical etidronate appears to prevent bone loss associated with prednisone treatment in patients with primary biliary cirrhosis. These preliminary results encourage the further evaluation of long term prednisone treatment and concurrent bisphosphonate therapy in primary biliary cirrhosis.
authors.affiliation: Department of Internal Medicine II (section Hepatology), University Hospital Rotterdam, The Netherlands.
authors.forename: F H
authors.initials: FH
authors.lastname: Wolfhagen
authors.forename: H R
authors.initials: HR
authors.lastname: van Buuren
authors.forename: J W
authors.initials: JW
authors.lastname: den Ouden
authors.forename: W C
authors.initials: WC
authors.lastname: Hop
authors.forename: J P
authors.initials: JP
authors.lastname: van Leeuwen
authors.forename: S W
authors.initials: SW
authors.lastname: Schalm
authors.forename: H A
authors.initials: HA
authors.lastname: Pols
mesh_terms: D000305:Adrenal Cortex Hormones / Q000009:adverse effects*; D000328:Adult; D000368:Aged; D015519:Bone Density / Q000187:drug effects; D004311:Double-Blind Method; D012968:Etidronic Acid / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008105:Liver Cirrhosis, Biliary / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000517:prevention & control*; D010865:Pilot Projects; D011446:Prospective Studies
chemical_list: D000305:Adrenal Cortex Hormones; D012968:Etidronic Acid